Antibodies 14F7 and the corresponding anti-idiotype 1E10 (racotumomab, misspelled as racotumumab) were mistakenly conflated in this review. 14F7 reacts with (Neu5Gc)GM3, was recently humanized (1), but has not yet been tested in clinical trials. Racotumomab induced a human anti-(Neu5Gc)GM3 immune response, which correlated with longer median survival in non-small cell lung cancer (2). The first clinical trial result using racotumomab was actually published in 2002 (3). A phase III trial testing racotumomab in advanced non-small cell lung cancer began in 2011, and is currently recruiting (NCT01460472). These studies do not consider dietary Neu5Gc intake and incorporation as a variable that could affect (Neu5Gc)GM3 expression by human cancers.
Statements
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
Fernández-MarreroYRoque-NavarroLHernándezTDorvignitDMolina-PérezMGonzálezAet alA cytotoxic humanized anti-ganglioside antibody produced in a murine cell line defective of N-glycolylated-glycoconjugates. Immunobiology (2011) 216:1239–47.10.1016/j.imbio.2011.07.004
2
HernándezAMToledoDMartínezDGriñánTBritoVMacíasAet alCharacterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody. J Immunol (2008) 181:6625–34.
3
AlfonsoMDíazAHernándezAMPérezARodríguezEBittonRet alAn anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients. J Immunol (2002) 168:2523–9.
Summary
Keywords
Neu5Gc, sialic acid, antibodies, inflammation, tumor antigen, red meat
Citation
Samraj AN, Läubli H, Varki N and Varki A (2014) Corrigendum: Involvement of a Non-Human Sialic Acid in Human Cancer. Front. Oncol. 4:83. doi: 10.3389/fonc.2014.00083
Received
02 April 2014
Accepted
04 April 2014
Published
22 April 2014
Volume
4 - 2014
Edited and reviewed by
Adriane Regina Todeschini, Universidade Federal do Rio de Janeiro, Brazil
Copyright
© 2014 Samraj, Läubli, Varki and Varki.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: a1varki@ucsd.edu
This article was submitted to Molecular and Cellular Oncology, a section of the journal Frontiers in Oncology.
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.